List view / Grid view
A study that identified 12 novel compounds that may prove valuable against new drug targets for leishmaniasis and Chagas disease was not without complication. Here, we discuss the findings but also the challenges the researchers reported in their hit-to-lead study.
The expression of PI3Ky increases during infection by T.cruzi, providing an essential response controlling the parasite and avoiding inflammation...
Researchers have discovered a new potential therapeutic target – located in the ribosome – to combat trypanosomes parasites...
Researchers have used a multi-modal integrated approach to develop potential new anti-Chagas therapies...
The collaboration will provide MSc students with industry-relevant learning tools and pharma with a new pipeline of candidate compounds.
Daiichi Sankyo has entered into a new joint research agreement with the Drugs for Neglected Diseases initiative (DNDi) with regard to a new research program, the Hit-to-Lead Project, with the aim of developing drug treatments for two neglected tropical diseases, leishmaniasis and Chagas disease.
9 August 2016 | By Niamh Louise Marriott, Digital Content Producer
Three diseases; Chagas disease, leishmaniasis and sleeping sickness, all caused by parasites called ‘kinetoplastids, all sharing similar biology and genetics, leading scientists to investigate the possibility of a single chemical to destroy all three...
